Evaluation of phenotypic and genotypic methods for detecting KPC variants
- PMID: 40178306
- PMCID: PMC12057356
- DOI: 10.1128/aac.00082-25
Evaluation of phenotypic and genotypic methods for detecting KPC variants
Abstract
Klebsiella pneumoniae carbapenemases (KPCs) have spread and diversified extensively. To date, 242 clinical variants have been identified and harbor different hydrolytic capacities, thereby interfering with rapid diagnostic tests. The accurate detection of KPC variants is crucial to guide treatment and control measures in healthcare settings. We constructed KPC variants to assess the mutational impact on detection capacities of resistance-based tests. KPC variants (n = 45) were characterized phenotypically and used to measure the detection sensitivity of KPC detection methods (two lateral flow immunoassays [LFIAs], three hydrolysis tests, three selective culture media, and two PCR-based tests). We identified four antibiotic susceptibility patterns: "KPC-like" (23/45; 51%), "extended-spectrum beta-lactamase-like" (6/45; 13%), "ceftazidimase" (9/45; 20%), and outlier variants with "mixed-profiles" (5/45; 11%). These phenotypes had different impacts on the detection capabilities of hydrolysis tests (0%-100%), LFIA (44%-100%), and selective culture media (0%-100%), highlighting a risk of misdiagnosis for some KPC variants. All variants were detected with PCR-based tests. To detect the maximum of KPC variants, fecal carriage screening requires a combination of selective media targeting resistance to carbapenems, third-generation cephalosporins, and ceftazidime-avibactam. From antibiotic susceptibility testing, resistance to ceftazidime ± avibactam and specific phenotypic profiles should be used as warnings to track the presence of KPC variants. We recommend LFIA as a first-line test, owing to its high sensitivity in detecting KPC variants. Nevertheless, using a combination of tests may remain wise in some situations. The spread of KPC variants remains a significant concern, particularly as reversion to ancestral phenotype could restore carbapenem resistance and lead to therapeutic failure.
Keywords: KPC beta-lactamase; LFIA tests; clinical KPC variants; detection tests; hydrolysis-based tests.
Conflict of interest statement
The authors declare no conflict of interest.
Figures


Similar articles
-
Antimicrobial resistance and phylogenetic lineages of KPC-2-producing blood-borne Klebsiella pneumoniae subsp. pneumoniae from Kolkata, India during 2015-2024: Emergence of Klebsiella pneumoniae subsp. pneumoniae with blaKPC-2, blaNDM, and blaOXA-48-like triple carbapenemases.Microbiol Spectr. 2025 Aug 5;13(8):e0012625. doi: 10.1128/spectrum.00126-25. Epub 2025 Jun 12. Microbiol Spectr. 2025. PMID: 40503825 Free PMC article.
-
Cefepime-taniborbactam and ceftibuten-ledaborbactam maintain activity against KPC variants that lead to ceftazidime-avibactam resistance.Antimicrob Agents Chemother. 2025 Mar 5;69(3):e0151124. doi: 10.1128/aac.01511-24. Epub 2025 Feb 10. Antimicrob Agents Chemother. 2025. PMID: 39927783 Free PMC article.
-
Evolution of ceftazidime-avibactam resistance driven by variation in bla KPC-2 to bla KPC-190 during treatment of ST11-K64 hypervirulent Klebsiella pneumoniae.Front Cell Infect Microbiol. 2025 Jun 6;15:1607127. doi: 10.3389/fcimb.2025.1607127. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40546282 Free PMC article.
-
Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports.Ann Clin Microbiol Antimicrob. 2012 Dec 13;11:32. doi: 10.1186/1476-0711-11-32. Ann Clin Microbiol Antimicrob. 2012. PMID: 23234297 Free PMC article.
-
Antibody tests for identification of current and past infection with SARS-CoV-2.Cochrane Database Syst Rev. 2022 Nov 17;11(11):CD013652. doi: 10.1002/14651858.CD013652.pub2. Cochrane Database Syst Rev. 2022. PMID: 36394900 Free PMC article.
Cited by
-
Detection of β-lactam resistance genes in Gram-negative bacteria from positive blood cultures using a microchip-based molecular assay.Front Cell Infect Microbiol. 2025 Jun 3;15:1597700. doi: 10.3389/fcimb.2025.1597700. eCollection 2025. Front Cell Infect Microbiol. 2025. PMID: 40529307 Free PMC article.
References
-
- Zhanel GG, Lawson CD, Adam H, Schweizer F, Zelenitsky S, Lagacé-Wiens PRS, Denisuik A, Rubinstein E, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2013. Ceftazidime-avibactam: a novel cephalosporin/β-lactamase inhibitor combination. Drugs (Abingdon Engl) 73:159–177. doi:10.1007/s40265-013-0013-7 - DOI - PubMed
-
- Zhanel GG, Lawrence CK, Adam H, Schweizer F, Zelenitsky S, Zhanel M, Lagacé-Wiens PRS, Walkty A, Denisuik A, Golden A, Gin AS, Hoban DJ, Lynch JP, Karlowsky JA. 2018. Imipenem–relebactam and meropenem–vaborbactam: two novel carbapenem-β-lactamase inhibitor combinations. Drugs (Abingdon Engl) 78:65–98. doi:10.1007/s40265-017-0851-9 - DOI - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical